Peptides

Melanotan II: What It Is, Safety Concerns, and FDA Warnings

Medically reviewed by Medical Advisory Board Last reviewed 2026-07-20

A synthetic tanning peptide with real, documented safety concerns — not an FDA-approved product

Melanotan II (MT2) is an unapproved synthetic peptide sold online for skin tanning and, informally, libido. It has a documented side-effect profile including nausea, flushing, spontaneous erections, and darkening of existing moles, plus FDA and international regulatory warnings about unregulated injectable tanning products.

This article is for informational purposes only and is not medical advice. Consult a physician for medical guidance.

Melanotan II (often shortened to MT2) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), the same natural hormone family that drives skin pigmentation. It was originally developed in the 1980s by researchers at the University of Arizona studying sunless-tanning and skin-cancer-prevention strategies. It has never received FDA approval for any use and is not a legally marketed drug or cosmetic product in the United States. Despite that, it circulates widely online as an injectable “tanning peptide,” typically self-administered without medical supervision.

Want expert help with your metabolic health?

We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.

Book An Appointment With A Specialist →

This page exists because the search demand for Melanotan II is real and substantial, and because the safety information available to people encountering it online is inconsistent. The framing here is deliberately safety-first rather than a how-to-use guide.

How It's Marketed vs. What's Actually Approved

MT2 is commonly marketed online for two effects: accelerating and darkening a tan (by stimulating melanin production independent of UV exposure) and, informally, increasing libido. Neither use is FDA-approved for MT2 itself.

It's worth distinguishing MT2 from its better-known relative, bremelanotide (brand name Vyleesi), which the FDA did approve in 2019 — specifically for hypoactive sexual desire disorder in premenopausal women, administered as a single-use auto-injector under a physician's prescription, with a formally studied dose and monitored side-effect profile. Bremelanotide was derived from the same melanocortin-receptor research family as Melanotan II, but the two are different compounds with different regulatory status: one is an approved prescription drug with clinical trial data behind its labeled use, the other is an unregulated research chemical with no approved use at all. Products marketed simply as “Melanotan II” for tanning are not Vyleesi and do not carry its safety and quality assurances.

Melanotan II vs PT-141 (Bremelanotide): Head-to-Head

Because both peptides come from the same melanocortin-receptor research family, people often ask how they actually compare rather than just that they're related. The table below puts the two side by side.

Factor	Melanotan II (MT2)	PT-141 / Bremelanotide (Vyleesi)
FDA status	Not FDA-approved for any use	FDA-approved (2019) for hypoactive sexual desire disorder in premenopausal women
Primary marketed use	Skin tanning (unapproved); informal libido use	Low sexual desire, on-label and clinically studied
Receptor selectivity	Broad melanocortin-receptor activation (MC1R, MC3R, MC4R)	More selective for MC4R, the receptor most tied to sexual arousal
Formulation and dosing	Unregulated research-chemical vials; no standardized dose	Single-use auto-injector with a fixed, studied dose
Tanning / pigmentation effect	Pronounced — the main reason it's used	Minimal at the approved dose; not marketed for tanning
Documented side effects	Nausea, flushing, spontaneous erections, mole darkening, injection-site reactions	Nausea, flushing, headache, transient blood pressure increase — studied in clinical trials
Sourcing	Unregulated online vendors; contamination/dosing risk	Pharmacy-dispensed, prescription-only

The verdict: PT-141 (Vyleesi) is the appropriate choice for its approved indication — low sexual desire — because it comes with a studied dose, pharmacy quality control, and a physician's oversight. Melanotan II is not a substitute for it and is not approved for any indication; its broader receptor activation is also what drives its pronounced (and unapproved) tanning effect and its mole-darkening risk, which PT-141 does not share at its approved dose. Anyone interested in the libido effect specifically should ask a physician about PT-141/Vyleesi rather than sourcing unregulated Melanotan II.

Documented Side Effects and Regulatory Warnings

Unlike some newer research peptides with limited human data, MT2 has a fairly well-documented — and concerning — side-effect profile from case reports, poison-control data, and regulatory reviews:

Nausea and flushing, especially with the first few doses, are the most commonly reported effects.
Spontaneous, sometimes prolonged erections have been reported in men — a direct consequence of the melanocortin receptor pathway also exploited by bremelanotide for its approved indication.
Darkening of existing moles and skin lesions has been documented, which is a specific dermatological concern: it can make it harder to visually monitor moles for changes suggestive of melanoma, and case reports exist of new or changing pigmented lesions appearing after MT2 use. Anyone with a personal or family history of melanoma or atypical moles should treat this as a significant red flag, not a cosmetic footnote.
Injection-site reactions and appetite suppression are also commonly reported.

Multiple national drug and medicines regulators outside the US, along with US poison control centers, have issued public warnings about unregulated injectable tanning products, citing the lack of quality control, unknown actual dosing in sold products, and the mole-darkening/melanoma-monitoring concern specifically. This is a materially different risk profile than most other research peptides discussed elsewhere on this site, most of which lack this volume of documented adverse-effect reporting simply because they are less widely used.

Sourcing and Legal Status

MT2 is sold in the US as an unregulated research chemical, meaning products are not manufactured, tested, or labeled to any pharmaceutical standard. Because it is injected rather than taken orally, sourcing quality is a direct safety issue: contamination, incorrect concentration, and non-sterile handling are realistic risks with any unregulated injectable product, independent of the specific pigmentation and cardiovascular concerns already documented for MT2 itself. It is not a scheduled controlled substance in the US, but it is also not a legally marketed drug or cosmetic — a distinction worth understanding before assuming “not illegal to possess” means “safe to inject.” For more on how peptide legal status works generally, see our guide on whether peptides are legal.

Anyone considering MT2 for any reason — and especially anyone with a personal or family history of skin cancer, atypical moles, or cardiovascular disease — should speak with a physician or dermatologist first.

Frequently Asked Questions

Is Melanotan II FDA-approved?

No. Melanotan II has never received FDA approval for any use, including tanning. It is sold only as an unregulated research chemical. Its chemical relative, bremelanotide (Vyleesi), is FDA-approved, but for a different indication (hypoactive sexual desire disorder) under a physician's prescription — that approval does not extend to Melanotan II or to unsupervised use of either compound for tanning.

Is Melanotan II safe?

It has a documented risk profile that includes nausea, flushing, spontaneous erections, and — notably — darkening of moles and skin lesions, which can interfere with monitoring for melanoma. Multiple regulators and poison control centers have issued public warnings about unregulated injectable tanning products. Anyone with a personal or family history of skin cancer or atypical moles should treat this as a significant concern and consult a physician or dermatologist rather than self-administering.

What's the difference between Melanotan II and PT-141 (bremelanotide)?

Both are melanocortin-receptor peptides derived from related research, but they are different compounds with different regulatory status. Bremelanotide is FDA-approved (brand name Vyleesi) specifically for hypoactive sexual desire disorder in premenopausal women, with an established prescription dose and monitored safety profile. Melanotan II is not FDA-approved for any use and is sold only as an unregulated research chemical, primarily marketed for tanning.

Why does Melanotan II darken moles?

Melanotan II works by stimulating melanocortin receptors that drive melanin production throughout the skin, not just in areas exposed to sun. Existing moles and pigmented lesions contain melanocytes and can darken along with the rest of the skin. This is a specific documented concern because it can obscure the visual changes that dermatologists and patients rely on to catch melanoma early.

Topic updates

Get the weekly peptide roundup

Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

Check Where You Stand

Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results